Evidence map›Paper›PMID 38712314›Full record

ArticleRespiratory medicine case reports2024

Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis.

Taisuke Ito, Kazuo Tsuchiya, Rie Mori, Takuro Akashi, Yoshiyuki Oyama, Masaki Ikeda

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Taisuke ItoDepartment of Respiratory Medicine, Shizuoka Saiseikai General Hospital, Shizuoka City, Shizuoka, Japan.
Kazuo TsuchiyaDepartment of Respiratory Medicine, Shizuoka Saiseikai General Hospital, Shizuoka City, Shizuoka, Japan.
Rie MoriDepartment of Respiratory Medicine, Shizuoka Saiseikai General Hospital, Shizuoka City, Shizuoka, Japan.
Takuro AkashiDepartment of Respiratory Medicine, Shizuoka Saiseikai General Hospital, Shizuoka City, Shizuoka, Japan.
Yoshiyuki OyamaDepartment of Respiratory Medicine, Shizuoka Saiseikai General Hospital, Shizuoka City, Shizuoka, Japan.
Masaki IkedaDepartment of Respiratory Medicine, Shizuoka Saiseikai General Hospital, Shizuoka City, Shizuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 60-year-old woman was diagnosed with cT4N3M1c stage IVB lung adenocarcinoma with epidermal growth factor receptor mutation of exon19 deletion. After one month of treatment with osimertinib, a cough and diffuse ground glass opacities were observed in the bilateral lung field. Based on the clinical course and the exclusion of other etiologies, osimertinib-induced pneumonitis was diagnosed. The shadows resolved after osimertinib was discontinued. However, brain metastasis and leptomeningeal metastasis developed 20 months later; therefore, osimertinib was re-administered without concomitant corticosteroids. The pulmonary lesion and leptomeningeal metastasis were successfully treated without recurrence of drug-induced pneumonitis for eight months.

Indexed as

DesensitizationEGFR-TKIOsimertinibOsimertinib-induced pneumonitisRe-administration

Identifiers

PMID38712314
PMCPMC11070756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.